BioRestorative Therapies, a life sciences company focussed on adult stem cell-based therapies for various personal medical applications, announced the engagement of Tokyo-based Solution Partners Ltd. to develop strategic alliances in Japan and China for the company's technologies.

The agreement includes introductions to potential strategic partners and other alliance candidates, with the goal of expansion and development of the company's ThermoStem programme, the company's stem cell delivery device used in connection with the company's brtx-DISC programme and the company's brtx-C Cosmetic programme.

Solution Partners, founded by Masami Ishigaki in 2000, is an official supporting member of Tokyo Metropolitan Hospital Association. Ishigaki has served in various financial positions at, among others, Suntory, Novartis Pharma (Japan), and LVMH Group (Guerlain Japan and Celine Japan).

"Solution Partners has a strong track record of success in identifying and negotiating strategic alliances in Japan and China, and we are very excited to engage Ishigaki and his firm to identify business possibilities for us," said Mark Weinreb, BioRestorative Therapies' chief executive officer. "These Asian markets are very large, and represent significant potential opportunities for our proprietary stem cell programmes. We look forward to continuing our work on ThermoStem and brtxDISC in the US while expanding the worldwide market for our therapies. In addition, Ishigaki's experience in the cosmetics field is expected to support our goal of licencing brtx-C Cosmetic technologies to skincare companies."

Solution Partners has provided quality improvement programmes for medical care and nursing systems, hospital infection control, hospital information systems and recruitment services for professional medical staff. It is also engaged in marketing and sales support for genetic testing for cancer, developed by Japanese company Genescience Ltd. in  Japan and in China.

BioRestorative Therapies, develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including: brtxDISC (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery.